These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8722416)

  • 41. Improving the efficacy of antibody-based cancer therapies.
    Carter P
    Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [An overview of antibody-based cancer therapy].
    Miao QF; Shao RG; Zhen YS
    Yao Xue Xue Bao; 2012 Oct; 47(10):1261-8. PubMed ID: 23289136
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibodies in the treatment of human cancer.
    Kuzel TM; Rosen ST
    Curr Opin Oncol; 1994 Nov; 6(6):622-6. PubMed ID: 7827176
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Introduction to the supplement, "Cancer Therapy with Antibodies and Immunoconjugates".
    Goldenberg DM
    Cancer; 2010 Feb; 116(4 Suppl):1011-2. PubMed ID: 20127946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective.
    Press OW
    Semin Oncol; 2003 Apr; 30(2 Suppl 4):10-21. PubMed ID: 12728403
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
    Witzig TE
    Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
    Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF
    Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can preirradiation enhance tumor uptake of radiolabeled pharmaceuticals? Experimental data in a mouse neuroblastoma xenograft system.
    Sautter-Bihl ML; Bihl H
    Recent Results Cancer Res; 1996; 141():123-35. PubMed ID: 8722423
    [No Abstract]   [Full Text] [Related]  

  • 49. [Monoclonal antibody therapy: a literature review].
    Del Debbio CB; Tonon LM; Secoli SR
    Rev Gaucha Enferm; 2007 Mar; 28(1):133-42. PubMed ID: 17658067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer.
    Trail PA; King HD; Dubowchik GM
    Cancer Immunol Immunother; 2003 May; 52(5):328-37. PubMed ID: 12700948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted radioimmunotherapy: the role of ¹³¹I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas.
    Hdeib A; Sloan A
    Future Oncol; 2012 Jun; 8(6):659-69. PubMed ID: 22764763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of antibodies and immunoconjugates for the therapy of more accessible cancers.
    Sharkey RM; Goldenberg DM
    Adv Drug Deliv Rev; 2008 Sep; 60(12):1407-20. PubMed ID: 18508155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radioimmunotherapy of orthotopically transplanted pancreatic cancer with 131I-labeled chimeric monoclonal antibody Nd2.
    Yamamoto A; Sawada T; Yamashita Y; Nishihara T; Ho JJ; Kim Y; Chung KH
    Oncol Rep; 1999; 6(1):179-84. PubMed ID: 9864424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
    Juweid ME; Hajjar G; Swayne LC; Sharkey RM; Suleiman S; Herskovic T; Pereira M; Rubin AD; Goldenberg DM
    Cancer; 1999 Apr; 85(8):1828-42. PubMed ID: 10223579
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody-drug conjugate for advanced melanoma?
    Sharma SP
    Lancet Oncol; 2014 Nov; 15(12):e534. PubMed ID: 25602109
    [No Abstract]   [Full Text] [Related]  

  • 56. Antibody conjugate therapeutics: challenges and potential.
    Teicher BA; Chari RV
    Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ImmunoGen Inc. Immunoconjugates in canacer therapy: if at first you don't succeed, try, try again.
    Ballew N
    Chem Biol; 2003 Sep; 10(9):781-2. PubMed ID: 14522046
    [No Abstract]   [Full Text] [Related]  

  • 58. The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates.
    Hopkins K; Papanastassiou V; Kemshead JT
    Recent Results Cancer Res; 1996; 141():159-75. PubMed ID: 8722426
    [No Abstract]   [Full Text] [Related]  

  • 59. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.
    Lindén O; Kurkus J; Garkavij M; Cavallin-Ståhl E; Ljungberg M; Nilsson R; Ohlsson T; Sandberg B; Strand SE; Tennvall J
    Cancer Biother Radiopharm; 2005 Aug; 20(4):457-66. PubMed ID: 16114994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.